Germany is one of the leading nations in the field of basic medical research. However, despite outstanding expertise and groundbreaking discoveries, medical innovations "Made in Germany" remain rare. Why does it take so long for groundbreaking developments to reach market maturity? What are the challenges along the way? And why does the promotion of broad-based basic research remain essential for the success of our healthcare industry?

In an exclusive panel discussion, Prof. Dr. med. Dr. h.c. Matthias Tschöp, CEO of Helmholtz Munich, sheds light on the immense importance of basic research for Germany as a center of science. He explains how this research contributes to long-term value creation and is crucial for the development of new medical therapies.

Dr. Daniel Steiners, CEO of Roche Pharma AG, will provide an exciting insight into the perspective of the pharmaceutical industry and explain how closely cooperation with basic research is interlinked. He will show what further steps are necessary before a drug is approved and what opportunities and challenges lurk along the way.

Experience a high-caliber discussion with leading minds from the industry and discuss the future of medical research and innovation in Germany with our experts.

Join us and take a look behind the scenes of medical research and pharmaceutical development.

Prof. Dr. med. Dr. h.c. Matthias Tschöp is CEO of Helmholtz Munich and a leading expert in the research of metabolic diseases, in particular diabetes and obesity. He holds a doctorate in medicine and has developed several innovative therapies targeting hormonal balance to treat metabolic disorders.

Dr. Daniel Steiners is a member of the Executive Board of Roche Pharma AG in Germany. With international experience in the USA and Japan, Steiners brings extensive expertise in marketing, sales and global strategy development. His focus at Roche is on ensuring access to innovative therapies for seriously ill patients in Germany.

About Helmholtz Munich:

Helmholtz Munich is a biomedical research center of excellence. Its mission is to develop breakthrough solutions for a healthier society in a rapidly changing world. Interdisciplinary research teams focus on environmental diseases, in particular the treatment and prevention of diabetes, obesity, allergies and chronic lung diseases. Using artificial intelligence and bioengineering, the researchers transfer their findings to patients more quickly. Helmholtz Munich has around 2,500 employees and is based in Munich/Neuherberg. It is a member of the Helmholtz Association, the largest scientific organization in Germany with more than 43,000 employees and 18 research centers.